What's New in the Guidelines
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format and updated as relevant changes in prevention and treatment recommendations occur.
All changes are developed by the subject-matter groups listed in the document. (Changes in group composition also are posted promptly.) These changes are reviewed by the editors and relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:
September 25, 2023
- Updated data on incidence.
- Provided information on ocular syphilis.
- Updated the discussion of diagnostic algorithms.
- Provided information on doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections.
- Provided information on the availability of benzathine penicillin and procaine penicillin.
- Updated to include medications used for the treatment of mpox.
September 7, 2023
- Hepatitis B Vaccine
- Updated recommendations for Heplisav-B for primary vaccination and for nonresponders to other primary regimens.
- Meningococcal Vaccine
- Updated recommendations regarding quadrivalent meningococcal conjugate vaccines.
- Pneumococcal Vaccine
- Updated recommendations regarding use of PCV 15 and PCV 20.
July 24, 2023
- Added new mpox chapter covering the epidemiologic, diagnostic, prevention, and treatment considerations for people with HIV.
June 14, 2023
- Updated information on the epidemiology of Chagas disease.
- Updated information on nifurtimox administration and its approval status with the U.S. Food and Drug Administration.